The Latest Breaking News from Pfizer

Pfizer is taking on Amgen with its next steps in weight loss, the pharma titan said Tuesday as Pfizer stock dipped despite its beat.

December S&P 500 E-Mini futures (ESZ24) are up +0.06%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.08% this morning as market participants geared up for the latest reading on U.S. job openings while also awaiting a deluge of corporate earnings reports from heavyweight names.

Analysts say gold is benefited from safe-haven demand amid persistent geopolitical tensions, expectations of monetary policy easing, and mounting uncertainty surrounding the US presidential election.

Pfizer is getting back on track—but an even more potent prescription for success could be in the cards for the pharmaceutical giant under.

Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.

Pfizer spinoff Kenvue led the S&P 500 on Monday. Nvidia stock was close behind, breaking out to a record high.

Pfizer is expected to release its fiscal third-quarter earnings later this month, and analysts project a triple-digit profit growth.

This dividend stock is now on the radar of activist investors, with Starboard eyeing a possible management shakeup.

Paul Hudson, the Briton in charge of the French drug firm, is a big believer in the potential of AI to transform healthcare

Nvidia is expected to boost the S&P 500 Q3 earnings growth rate. Meta Platforms and Alphabet may lift Communications Services earnings.

Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments.